Edition:
United Kingdom

People: WAVE Life Sciences Ltd (WVE.OQ)

WVE.OQ on NASDAQ Stock Exchange Global Market

47.30USD
5:37pm BST
Change (% chg)

$0.50 (+1.07%)
Prev Close
$46.80
Open
$46.55
Day's High
$47.90
Day's Low
$46.55
Volume
7,475
Avg. Vol
60,224
52-wk High
$55.95
52-wk Low
$16.10

Regnante, Keith 

Mr. Keith Regnante is the Chief Financial Officer of the Company. He has held financial leadership roles within the biotechnology space for over 15 years. Prior to joining the Company, from February 2014 to August 2016, Mr. Regnante served as Vice President of Finance of Shire Pharmaceuticals, a global biopharmaceutical company. Mr. Regnante also served on the Financial Leadership Team and the R&D Leadership Team while he was at Shire. From September 2013 to February 2014, he served as Head of R&D Finance for ARIAD Pharmaceuticals, Inc. From January 1999 to August 2013, Mr. Regnante held multiple positions within finance for Biogen Inc., including Senior Director of Corporate Finance from 2011 to 2013, Senior Director of Worldwide R&D Finance from 2008 to 2011, and several other positions dating back to 1999. Prior to joining finance organizations for biotechnology companies, Mr. Regnante worked as a consultant at The Boston Consulting Group. He holds a B.A. in Economics from Tufts University and an M.B.A. from the MIT Sloan School of Management.

Basic Compensation

Total Annual Compensation, USD 120,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,519,220
Fiscal Year Total, USD 1,639,220

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Gregory Verdine

156,901

Paul Bolno

3,594,860

Keith Regnante

1,639,220

Christopher Francis

160,763

Chandra Vargeese

151,724

Michael Panzara

2,762,040
As Of  31 Dec 2016